The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
Open accessAbstract
Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment. Therefore, understanding the mechanisms underlying chemoresistance is mandatory to improve treatments' outcome. We generated TMZ resistant cells (TMZ-R) from a GBM cell line and from cancer stem cell-enriched cultures isolated from human GBMs. We demonstrated that TMZ resistance is partially reverted by "drug wash-out" suggesting the contribution of epigenetic mechanisms in drug resistance and supporting the possibility of TMZ rechallenge in GBM patients after prior drug exposure. The expression of histone lysine demethylase genes (KDMs) was increased in TMZ-R cells compared to parental cells, and TMZ resistance or restored sensitivity was mimicked by over-expressing or inactivating KDM5A. Methylation and expression of O6-methylguanine-DNA methyltransferase (MGMT) and drug efflux mechanisms were not altered in TMZ-R cells compared to parental TMZ sensitive cells. TMZ-R cells transiently acquired morphologic and molecular characteristics of differentiated tumor cells, features that were lost after drug wash-out. In conclusion, we demonstrated that treatment-induced TMZ resistance in GBM involves epigenetic mechanisms in a subset of slow-cycling and transiently partially differentiated cells that escape drug cytotoxicity, overcome G2 checkpoint and sustain clonal growth. We found that TMZ-R cells are sensitive to histone deacethylase inhibitors (HDACi) that synergize with TMZ. This strong synergism could be exploited to develop novel combined adjuvant therapies for this rapidly progressing and invariably lethal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Persisters are able to maintain viability under therapy but are typically slow cycling or dormant.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., HAVEMAN, J., & Chris van, B. R. E. E. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,202
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
ABC transporters in cancer: more than just drug efflux pumps
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2789 · Cited by 1,052
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 741
Temozolomide and treatment of malignant glioma.
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · Cited by 722
Research works printed but not linked: 3
- Cahill DP, 2008, Clin Neurosurg, 55, 165
- Hou J, 2012, Am J Transl Res, 4, 247
- Friedman HS, 2000, Clin Cancer Res, 6, 2585
Cited by
Sorted by citations
Items 101–137 of 137
Palla, A., Lin, C.-C., Trnka, M. J., Leao, E. M., Petronikolou, N., Burlingame, A. L., McGinty, R. K., & Fujimori, D. G. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169301 · Cited by 3
Zhang, C., Zeng, J., Ye, C., Tian, K., & Xian, Z. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1383 · Cited by 3
Oliveira, M. N., de Santana, L. L. B., Serafim, J. C., Santos, A. O., Quintino, M. P., Correia, J. T. M., Damasceno, F., Sabino, J. R., Cardim-Pires, T. R., Coelho, P. L. C., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00877-2 · Cited by 3
Chromatin Regulatory Targets for Anticancer Therapeutics
Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2
Li, X., Ren, Y., Pei, S., Zhao, K., Chen, G., & He, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1758433 · Cited by 2
Mechanism of Therapeutic Action of Rhodium Complexes
Hussain, A., Alajmi, M. F., Lone, M. A., & Wani, W. A. (2023) · Springer briefs in molecular science · doi:10.1007/978-3-031-35631-5_4 · Cited by 2
Serendipity in Neuro-Oncology: The Evolution of Chemotherapeutic Agents
Nadora, D., Ezzati, S., Bol, B., & Aboud, O. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072955 · Cited by 2
Lysine demethylases and cancer
Eckschlager, T., Vícha, A., & Frolikova, D. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156011 · Cited by 2
Epigenetics, Public Health, Lifestyle, and Chemoprevention
Romani, M., & Banelli, B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00018-4 · Cited by 2
Self-citationBibliometric and visualization analysis in the field of epigenetics and glioma (2009–2024)
Zeng, Y., Tao, G., Zeng, Y., He, J., Cao, H., & Zhang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1431636 · Cited by 1
Zawadzka, K., Wójcik, B., Sosnowska, M., Kutwin, M., Jaworski, S., Ostrowska, A., Pruchniewski, M., & Wierzbicki, M. (2025) · Nanotechnology Science and Applications · doi:10.2147/nsa.s540050 · Cited by 1
DNA and Histone Modifications in Cancer Therapy
Suzuki, T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_20 · Cited by 1
KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic
Zhang, S., Cao, J. P., & Yan, Q. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-38176-8_6 · Cited by 2
Cacabelos, R., Naidoo, V., Tellado, I., Corzo, L., Cacabelos, N., Cacabelos, P., Martínez-Iglesias, O. A., & Segre, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00029-3 · Cited by 1
The Response of Cancer Cell Populations to Therapies
Lindsay, D., Garvey, C. M., Mumenthaler, S. M., & Foo, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804310-3.00010-7 · Cited by 1
Novel Targets in the Treatment of Neuroendocrine Tumors: RBP2
Maggi, E. C., & Crabtree, J. S. (2017) · International Journal of Endocrine Oncology · doi:10.2217/ije-2016-0022 · Cited by 1
Kala, E. Y., Aksu, F. S., Ercan, M. E., Ozbıyık, A., Cingöz, A., Yedier-Bayram, O., Aksu, A. C., Cavga, A. D., Yilmaz, E., Kok, İ., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.09.653010 · Cited by 2
Harisankar, A. (2018) · Figshare
Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy
Verma, M., & Kumar, V. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_9
Combinatorial Genetic Screening in Cancer
Najm, F. J. (2019) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Histone lysine demethylase inhibitor (HDMi) as chemo-sensitizing agent
Shen, A., & Yu, X. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823684-0.00007-4
Zhang, T., Yuan, L., Sheng, M., Chen, Y., Wang, J., & Lan, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840394
The Role of Kdm5d in the Development of Chemoresistance to Cisplatin Through Cul4a in NeuroblastomaPreprint
Podhorska, N., Hraběta, J., Belhajová, M., & Eckschlager, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3659316/v1
Palla, A., Lin, C.-C., Trnka, M. J., Leao, E. M., Petronikolou, N., Burlingame, A. L., McGinty, R. K., & Fujimori, D. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.01.651538
Wu, J., Ku, S., Lagunas, A. M., & Crowe, D. L. (2026) · Molecular Carcinogenesis · doi:10.1002/mc.70109
Glioblastoma resistance to temozolomide : implication of α5β1 integrin and p53 signalling pathways
Sani, S. (2020) · theses.fr (ABES) · doi:10.70675/9566c585z0508z455bz9064z6bb61435b210
Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2
Non-genetic regulation of chemopersistence in Triple Negative Breast Cancers
Baudre, L. (2024) · theses.fr (ABES) · doi:10.70675/6422f0bbza832z4dcfza920zaa55605f8a31
Aksu, F., Cevatemre, B., Degirmenci, N. P., Kala, E. Y., Uçku, D., Philpott, M., Cribbs, A. P., Dunford, J. E., Oppermann, U. C. T., Açılan, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723296
Recent Advances in Research on Mechanisms of Chemotherapy Resistance in Glioblastoma
胡, 陵. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1682801
Sari, D. H., Wanandi, S. I., Aman, R. A., & Kasim, V. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12576-2
Astapczuk, J., Szewczyk-Roszczenko, O. K., Vassetzky, Y. S., & Czarnomysy, R. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108449
Piermartiri, T., da Matta, A. C. A., Pinto, J. V. K., Tasca, C. I., & Nedel, C. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1984427
Epigenetic personalized medicine in glioblastoma
Romani, M. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19043-8.00005-0
Self-citationBindingDB Entry 50018533: Pharmacological inhibition of KDM5A for cancer treatment.
BindingDB (2024) · UC San Diego · doi:10.7270/q2n01brw
BindingDB (2019) · UC San Diego · doi:10.7270/q2bc41z0
Metadata
- Authors
- Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., Florio, T., Daga, A., & Romani, M.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- University of Genoa (IT)
- Corresponding author
- Romani, Massimo
- ORCID
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2015-11-02
- Volume
- 14
- Issue
- 21
- Pages
- 3418-3429
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- PMC
- PMC4825557
- OpenAlex
- W2257580565
- Cited by
- 135
- References
- 57
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 8 · 2023: 12 · 2022: 13 · 2021: 19 · 2020: 10 · 2019: 12 · 2018: 15 · 2017: 12 · 2016: 9
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell Cycle (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Funders
- Compagnia di San Paolo
- Ministero della Salute (GR-2008-1143408)
- Associazione Italiana per la Ricerca sul Cancro (IG 13563)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- glioblastoma, temozolomide resistance, KDM5A, histone lysine demethylases, epigenetic drug resistance, cancer stem cells, tumor differentiation, G2 checkpoint, histone deacetylase inhibitors, chemoresistance, MGMT, drug efflux
- MeSH terms
- Temozolomide, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Cell Cycle, Cell Differentiation, Dacarbazine, Dose-Response Relationship, Drug, Drug Synergism, Genotype, Glioblastoma, Humans, Phenotype, Time Factors, Transfection, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Apoptosis, Antineoplastic Agents, Alkylating, Drug Resistance, Neoplasm, DNA Methylation, RNA Interference, Epigenesis, Genetic, Cell Line, Tumor, Cell Shape, Retinoblastoma-Binding Protein 2, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
